Arcus Capital Partners LLC Has $699,000 Stock Holdings in Danaher Co. (NYSE:DHR)

Arcus Capital Partners LLC lessened its holdings in shares of Danaher Co. (NYSE:DHR) by 11.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,800 shares of the conglomerate’s stock after selling 358 shares during the quarter. Arcus Capital Partners LLC’s holdings in Danaher were worth $699,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in DHR. AMF Tjanstepension AB acquired a new stake in shares of Danaher during the third quarter worth about $5,923,000. Wedge Capital Management L L P NC raised its holdings in Danaher by 3.2% during the 3rd quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate’s stock worth $342,000 after buying an additional 38 shares during the period. CX Institutional raised its holdings in Danaher by 5.5% during the 3rd quarter. CX Institutional now owns 2,908 shares of the conglomerate’s stock worth $808,000 after buying an additional 151 shares during the period. Creative Planning raised its holdings in shares of Danaher by 3.1% during the third quarter. Creative Planning now owns 126,340 shares of the conglomerate’s stock worth $35,125,000 after acquiring an additional 3,749 shares during the period. Finally, Magnus Financial Group LLC acquired a new stake in shares of Danaher during the third quarter worth $233,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analyst Weigh In

DHR has been the topic of several recent research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $277.00 price target (down previously from $299.00) on shares of Danaher in a research note on Thursday, January 30th. Stifel Nicolaus lifted their target price on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a research report on Wednesday, October 23rd. Stephens restated an “overweight” rating and issued a $315.00 target price on shares of Danaher in a research note on Wednesday, October 23rd. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Saturday, December 14th. Finally, Citigroup cut their price objective on shares of Danaher from $285.00 to $265.00 and set a “buy” rating on the stock in a research report on Thursday, January 30th. Seven research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.

Danaher Stock Performance

DHR opened at $203.56 on Friday. Danaher Co. has a 12-month low of $196.80 and a 12-month high of $281.70. The stock has a market cap of $147.03 billion, a price-to-earnings ratio of 38.55, a PEG ratio of 2.68 and a beta of 0.83. The business has a 50 day moving average of $230.49 and a 200-day moving average of $250.28. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the prior year, the business posted $2.09 earnings per share. On average, equities research analysts expect that Danaher Co. will post 7.67 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were given a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.53%. Danaher’s dividend payout ratio (DPR) is presently 20.45%.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the firm’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Company insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.